282 related articles for article (PubMed ID: 29517502)
1. Direct-acting antiviral treatment for patients with hepatocellular carcinoma.
Kushner T; Dieterich D; Saberi B
Curr Opin Gastroenterol; 2018 May; 34(3):132-139. PubMed ID: 29517502
[TBL] [Abstract][Full Text] [Related]
2. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
4. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
[TBL] [Abstract][Full Text] [Related]
5. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND
Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729
[TBL] [Abstract][Full Text] [Related]
6. The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis.
Huang P; Liu M; Zang F; Yao Y; Yue M; Wang J; Fan H; Zhuo L; Wu J; Xia X; Feng Y; Yu R
Carcinogenesis; 2018 Dec; 39(12):1497-1505. PubMed ID: 30602007
[TBL] [Abstract][Full Text] [Related]
7. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
8. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
Roche B; Coilly A; Duclos-Vallee JC; Samuel D
Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
[TBL] [Abstract][Full Text] [Related]
9. Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C.
Ahn YH; Lee H; Kim DY; Lee HW; Yu SJ; Cho YY; Jang JW; Jang BK; Kim CW; Kim HY; Park H; Cho HJ; Park B; Kim SS; Cheong JY
Gut Liver; 2021 May; 15(3):410-419. PubMed ID: 32893194
[TBL] [Abstract][Full Text] [Related]
10. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
Singal AG; Lim JK; Kanwal F
Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
[TBL] [Abstract][Full Text] [Related]
11. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
[TBL] [Abstract][Full Text] [Related]
13. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
[TBL] [Abstract][Full Text] [Related]
14. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
[TBL] [Abstract][Full Text] [Related]
15. Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals.
Tanaka S; Shinkawa H; Tamori A; Takemura S; Takahashi S; Amano R; Kimura K; Ohira G; Kawada N; Kubo S
J Surg Oncol; 2020 Dec; 122(8):1543-1552. PubMed ID: 32856301
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
[TBL] [Abstract][Full Text] [Related]
17. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis.
Guarino M; Viganò L; Ponziani FR; Giannini EG; Lai Q; Morisco F;
Dig Liver Dis; 2018 Nov; 50(11):1105-1114. PubMed ID: 30170908
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group.
Mashiba T; Joko K; Kurosaki M; Ochi H; Marusawa H; Uchida Y; Fujii H; Kojima Y; Yoshida H; Goto T; Akahane T; Kondo M; Tsuji K; Mitsuda A; Hasebe C; Kusakabe A; Sohda T; Furuta K; Kobashi H; Ogawa C; Ide Y; Arai H; Okada K; Shigeno M; Nonogi R; Izumi N
J Viral Hepat; 2022 Jul; 29(7):551-558. PubMed ID: 35548866
[TBL] [Abstract][Full Text] [Related]
19. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
[TBL] [Abstract][Full Text] [Related]
20. Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents.
Zou WY; Choi K; Kramer JR; Yu X; Cao Y; El-Serag HB; Kanwal F
Dig Dis Sci; 2019 Nov; 64(11):3328-3336. PubMed ID: 31041639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]